SEC Form 4 · accession 0001813798-26-000011
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jim Wassil
Officer — CHIEF OPERATING OFFICER
Period of report
Jun 1, 2026
Accepted (ET)
Jun 3, 2026 · 4:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 1, 2026 | S | 1,949 | $49.404 | D | 158,795 | D | |
| Common StockF3 | Jun 1, 2026 | S | 301 | $50.257 | D | 158,494 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
- F2The price reported is a weighted-average price. The shares were sold at prices ranging from $49.03 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The price reported is a weighted-average price. The shares were sold at prices ranging from $50.205 to $51.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.